GLP-1 agonists: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists | *Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists | ||
*Released by L-cells of the small | *Released by L-cells of the small intestine in response to the presence of nutrients | ||
*Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas | *Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas | ||
*Slows gastric emptying times | *Slows gastric emptying times | ||
| Line 12: | Line 12: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
*Nausea, vomiting, diarrhea | *[[Nausea]], [[vomiting]], [[diarrhea]] | ||
*Acute pancreatitis | *Acute [[pancreatitis]] | ||
*Exenatide should not be used in patients with creatinine clearance below 30mL/min | *Exenatide should not be used in patients with creatinine clearance below 30mL/min | ||
*Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B | *Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B | ||
| Line 23: | Line 23: | ||
==References== | ==References== | ||
#Epocrates | |||
#http://www.uptodate.com/contents/glucagon-like-peptide-1-receptor-agonists-for-the-treatment-of-type-2-diabetes-mellitus?source=see_link§ionName=GLUCAGON-LIKE+PEPTIDE-1&anchor=H2#H619400 | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Latest revision as of 20:35, 31 January 2024
Background
- Synthetic glucagon-like peptide-1 (GLP-1) receptor agonists
- Released by L-cells of the small intestine in response to the presence of nutrients
- Stimulate insulin release from pancreatic islet cells. It does this by stimulating glucose-dependent insulin release in the islet cells of the pancreas
- Slows gastric emptying times
- Increases satiety, which decreases drive for food intake
GLP-1 Agonist Types
| Short Acting | Dose |
|---|---|
| Exenatide (Byetta) | 5-10 mcg SC bid |
| Liraglutide (Victoza, Saxenda) | 0.6-1.8 mg SC daily |
| Long Acting | |
| Exenatide (Bydureon) | 2 mg SC qwk |
| Albiglutide (Tanzeum) | 30-50 mg SC qwk |
| Dulaglutide (Trulicity) | 0.75-1.5 mg qwk |
- Lixisenatide (Lyxumia, Adlyxin)
- Semaglutide (Ozempic, Rybelsus, Wegovy)
- Tirzepatide^ (Mounjaro, Zepbound)
^Dual GLP-1 and GIP agonist
Indication
- Diabetes Mellitus, Type 2
Adverse Reactions
- Nausea, vomiting, diarrhea
- Acute pancreatitis
- Exenatide should not be used in patients with creatinine clearance below 30mL/min
- Should not be used if personal of family history of medullary thyroid cancer or MEN 2A/2B